References
Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M,
et al. (2020). Effect of High vs Low Doses of Chloroquine Diphosphate
as Adjunctive Therapy for Patients Hospitalized With Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized
Clinical Trial. JAMA Network Open 3: e208857-e208857.
Capel RA, Herring N, Kalla M, Yavari A, Mirams GR, Douglas G, et
al. (2015). Hydroxychloroquine reduces heart rate by modulating the
hyperpolarization-activated current If: Novel electrophysiological
insights and therapeutic potential. Heart Rhythm 12: 2186-2194.
Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, Barbhaiya C,
et al. (2020). The QT interval in patients with COVID-19 treated with
hydroxychloroquine and azithromycin. Nature Medicine.
10.1038/s41591-020-0888-2
Durcan L, Clarke WA, Magder LS, & Petri M (2015). Hydroxychloroquine
Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing
Controversies and Improving Adherence. J Rheumatol 42:2092-2097.
Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker
AH, et al. (1991). Mortality and morbidity in patients receiving
encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression
Trial. N Engl J Med 324: 781-788.
Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et
al. (2020). Hydroxychloroquine and azithromycin as a treatment of
COVID-19: results of an open-label non-randomized clinical trial.
International Journal of Antimicrobial Agents: 105949.
Herring N, Kalla M, & Paterson DJ (2019). The autonomic nervous system
and cardiac arrhythmias: current concepts and emerging therapies. Nat
Rev Cardiol 16: 707-726.
Hinton D (2020). Food and Drug Administration. FDA Emergency use
authorization (EUA) of chloroquine and hydroxychloroquine. . Food and
Drug Administration. .
Huang CL (2017). Murine Electrophysiological Models of Cardiac
Arrhythmogenesis. Physiol Rev 97: 283-409.
January CT, & Riddle JM (1989). Early afterdepolarizations: mechanism
of induction and block. A role for L-type Ca2+ current. Circ Res
64: 977-990.
King JH, Huang CL, & Fraser JA (2013). Determinants of myocardial
conduction velocity: implications for arrhythmogenesis. Front Physiol
4: 154.
Lai PC, Ho W, Jain N, & Walters JD (2011). Azithromycin concentrations
in blood and gingival crevicular fluid after systemic administration. J
Periodontol 82: 1582-1586.
Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul
H, et al. (2020). Safety of hydroxychloroquine, alone and in
combination with azithromycin, in light of rapid wide-spread use for
COVID-19: a multinational, network cohort and self-controlled case
series study. medRxiv: 2020.2004.2008.20054551.
Lei M, & Huang CL-H (2019). Cardiac arrhythmogenesis: a tale of two
clocks? Cardiovascular Research. 10.1093/cvr/cvz283
Lei M, Wu L, Terrar DA, & Huang CL (2018). Modernized Classification of
Cardiac Antiarrhythmic Drugs. Circulation 138: 1879-1896.
Lenzer J (2020). Covid-19: US gives emergency approval to
hydroxychloroquine despite lack of evidence. BMJ 369: m1335.
Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton
SS, et al. (2020). Outcomes of hydroxychloroquine usage in United
States veterans hospitalized with Covid-19. medRxiv:2020.2004.2016.20065920.
Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et
al. (2020). Risk of QT Interval Prolongation Associated With Use of
Hydroxychloroquine With or Without Concomitant Azithromycin Among
Hospitalized Patients Testing Positive for Coronavirus Disease 2019
(COVID-19). JAMA Cardiology. 10.1001/jamacardio.2020.1834
Miller DR, Fiechtner JJ, Carpenter JR, Brown RR, Stroshane RM, &
Stecher VJ (1987). Plasma hydroxychloroquine concentrations and efficacy
in rheumatoid arthritis. Arthritis Rheum 30: 567-571.
Negami T, Araki M, Okuno Y, & Terada T (2019). Calculation of absolute
binding free energies between the hERG channel and structurally diverse
drugs. Sci Rep 9: 16586.
NIH (2020). NIH clinical trial of hydroxychloroquine, a potential
therapy for COVID-19, begins.
O’Hara T, Virág L, Varró A, & Rudy Y (2011). Simulation of the
undiseased human cardiac ventricular action potential: model formulation
and experimental validation. PLoS Comput Biol 7: e1002061.
Pharmafield (2020). Novartis sponsors hydroxychloroquine clinical trial
in hospitalised COVID-19 patientsed. Morriss E.
Reiz S, & Nath S (1986). Cardiotoxicity of local anaesthetic agents. Br
J Anaesth 58: 736-746.
Roden DM, Harrington RA, Poppas A, & Russo AM (2020). Considerations
for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus
Disease 2019) Treatment. Circulation. 10.1161/circulationaha.120.047521
Saleh M, Gabriels J, Chang D, Kim BS, Mansoor A, Mahmood E, et
al. The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on
the Corrected QT Interval in Patients with SARS-CoV-2 Infection.
Circulation: Arrhythmia and Electrophysiology 0.
doi:10.1161/CIRCEP.120.008662
Strauss DG, Gintant G, Li Z, Wu W, Blinova K, Vicente J, et al.(2018). Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a
Cardiac Safety Research Consortium / Health and Environmental Sciences
Institute / FDA Meeting. Therapeutic Innovation & Regulatory Science
53: 519-525.